Skip to main content

Articles

Page 18 of 21

  1. APOE, which encodes apolipoprotein E, is the most prevalent and best established genetic risk factor for late-onset Alzheimer’s disease. Current understanding of Alzheimer’s disease pathophysiology posits an impo...

    Authors: Andrew B Wolf, Jon Valla, Guojun Bu, Jungsu Kim, Mary Jo LaDu, Eric M Reiman and Richard J Caselli

    Citation: Alzheimer's Research & Therapy 2013 5:38

    Content type: Review

    Published on:

  2. The possibility to map amyloid-beta, the Alzheimer’s disease hallmark protein, in vivo opens the application for amyloid imaging in clinical trials with disease-modifying agents. Monitoring change in amyloid b...

    Authors: Rik Ossenkoppele, Niels D Prins and Bart NM van Berckel

    Citation: Alzheimer's Research & Therapy 2013 5:36

    Content type: Commentary

    Published on:

  3. Cognitive impairments, and particularly memory deficits, are a defining feature of the early stages of Alzheimer's disease and vascular dementia. Interventions that target these cognitive deficits and the asso...

    Authors: Alex Bahar-Fuchs, Linda Clare and Bob Woods

    Citation: Alzheimer's Research & Therapy 2013 5:35

    Content type: Review

    Published on:

  4. This paper summarizes the body of literature about early-onset dementia (EOD) that led to recommendations from the Fourth Canadian Consensus Conference on the Diagnosis and Treatment of Dementia. A broader dif...

    Authors: Mario Masellis, Kayla Sherborn, Pedro Rosa Neto, Dessa A Sadovnick, Ging-Yuek R Hsiung, Sandra E Black, Sadhana Prasad, Meghan Williams and Serge Gauthier

    Citation: Alzheimer's Research & Therapy 2013 5(Suppl 1):S7

    Content type: Review

    Published on:

    This article is part of a Supplement: Volume 5 Supplement 1

  5. Alzheimer's disease (AD) is a common neurodegenerative disease characterized by the accumulation of extracellular plaques and intracellular tangles. Recent studies support the hypothesis that the accumulation ...

    Authors: Kristin R Wildsmith, Monica Holley, Julie C Savage, Rebecca Skerrett and Gary E Landreth

    Citation: Alzheimer's Research & Therapy 2013 5:33

    Content type: Review

    Published on:

  6. The growing population of persons with dementia in Canada and the provision of quality care for this population is an issue that no healthcare authority will escape. Physicians often view dementia as a difficu...

    Authors: Cheryl Cook and Kenneth Rockwood

    Citation: Alzheimer's Research & Therapy 2013 5(Suppl 1):S6

    Content type: Review

    Published on:

    This article is part of a Supplement: Volume 5 Supplement 1

  7. While there have been no new medications approved for the treatment of Alzheimer's disease (AD) or other dementias in Canada since 2004, the Canadian Consensus Conference on the Diagnosis and Treatment of Deme...

    Authors: Nathan Herrmann, Krista L Lanctôt and David B Hogan

    Citation: Alzheimer's Research & Therapy 2013 5(Suppl 1):S5

    Content type: Review

    Published on:

    This article is part of a Supplement: Volume 5 Supplement 1

  8. The Fourth Canadian Consensus Conference on the Diagnosis and Treatment of Dementia (CCCDTD4) was held 3 to 4 May 2012 in Montreal, Quebec, Canada. A group of neuroimaging experts were assigned the task of rev...

    Authors: Amer M Burhan, Robert Bartha, Christian Bocti, Michael Borrie, Robert Laforce Jr, Pedro Rosa-Neto and Jean-Paul Soucy

    Citation: Alzheimer's Research & Therapy 2013 5(Suppl 1):S4

    Content type: Review

    Published on:

    This article is part of a Supplement: Volume 5 Supplement 1

  9. In May 2012, the Fourth Canadian Consensus Conference on the Diagnosis and Treatment of Dementia brought together in Montreal experts from around Canada to update Canadian recommendations for the diagnosis and...

    Authors: Jean-Paul Soucy, Robert Bartha, Christian Bocti, Michael Borrie, Amer M Burhan, Robert Laforce Jr and Pedro Rosa-Neto

    Citation: Alzheimer's Research & Therapy 2013 5(Suppl 1):S3

    Content type: Review

    Published on:

    This article is part of a Supplement: Volume 5 Supplement 1

  10. There have been several newly proposed sets of diagnostic criteria for Alzheimer's disease/mild cognitive impairment, advanced by the National Institute of Aging/Alzheimer's Association working groups in 2011 ...

    Authors: Howard Chertkow, Howard H Feldman, Claudia Jacova and Fadi Massoud

    Citation: Alzheimer's Research & Therapy 2013 5(Suppl 1):S2

    Content type: Review

    Published on:

    This article is part of a Supplement: Volume 5 Supplement 1

  11. Advances in the field of blood biomarker discovery will help in identifying Alzheimer's disease in its preclinical stage, allowing treatment to be initiated before irreversible damage occurs. This review discu...

    Authors: Veer Bala Gupta, Ramani Sundaram and Ralph N Martins

    Citation: Alzheimer's Research & Therapy 2013 5:31

    Content type: Review

    Published on:

  12. In a symposium held at the Clinical Trials in Alzheimer's Disease conference in Monte Carlo, Monaco (29 to 31 October 2012) three different, not mutually exclusive approaches to improve and facilitate clinical...

    Authors: René Spiegel, Rachelle S Doody, Suzanne Hendrix and Kristin Kahle-Wrobleski

    Citation: Alzheimer's Research & Therapy 2013 5:29

    Content type: Viewpoint

    Published on:

  13. Peripheral biomarkers to diagnose Alzheimer's disease (AD) have not been established. Given parallels between neuron and platelet biology, we hypothesized platelet membrane-associated protein changes may diffe...

    Authors: Laura E Donovan, Eric B Dammer, Duc M Duong, John J Hanfelt, Allan I Levey, Nicholas T Seyfried and James J Lah

    Citation: Alzheimer's Research & Therapy 2013 5:32

    Content type: Research

    Published on:

  14. Despite the extensive mechanistic and pathological characterization of the amyloid precursor protein (APP)/presenilin-1 (PS-1) knock-in mouse model of Alzheimer's disease (AD), very little is known about the A...

    Authors: Scott J Webster, Adam D Bachstetter and Linda J Van Eldik

    Citation: Alzheimer's Research & Therapy 2013 5:28

    Content type: Research

    Published on:

  15. Addressing causes of heterogeneity in cognitive outcomes is becoming more critical as Alzheimer's disease (AD) research focuses on earlier disease. One of the causes of this heterogeneity may be that individua...

    Authors: Suzanne B Hendrix and Kathleen A Welsh-Bohmer

    Citation: Alzheimer's Research & Therapy 2013 5:22

    Content type: Commentary

    Published on:

  16. Despite years of research, there are no disease-modifying drugs for Alzheimer's disease (AD), a fatal, age-related neurodegenerative disorder. Screening for potential therapeutics in rodent models of AD has ge...

    Authors: Marguerite Prior, Richard Dargusch, Jennifer L Ehren, Chandramouli Chiruta and David Schubert

    Citation: Alzheimer's Research & Therapy 2013 5:25

    Content type: Research

    Published on:

  17. Alzheimer's disease (AD), for which there is no cure, is the most common form of dementia in the elderly. Despite tremendous efforts by the scientific community, the AD drug development pipeline remains extrem...

    Authors: Laurent Lecanu and Vassilios Papadopoulos

    Citation: Alzheimer's Research & Therapy 2013 5:17

    Content type: Review

    Published on:

  18. The Alzheimer's disease (AD) epidemic is a looming crisis, with an urgent need for new therapies to delay or prevent symptom onset and progression. There is growing awareness that clinical trials must target s...

    Authors: Termpanit Chalermpalanupap, Becky Kinkead, William T Hu, Markus P Kummer, Thea Hammerschmidt, Michael T Heneka, David Weinshenker and Allan I Levey

    Citation: Alzheimer's Research & Therapy 2013 5:21

    Content type: Review

    Published on:

  19. During the past 20 years, the 5-HT6 receptor has received increasing attention and become a promising target for improving cognition. Several studies with structurally different compounds have shown that not only...

    Authors: María Javier Ramírez

    Citation: Alzheimer's Research & Therapy 2013 5:15

    Content type: Review

    Published on:

  20. Modulation of the gamma-secretase enzyme, which reduces the production of the amyloidogenic Aβ42 peptide while sparing the production of other Aβ species, is a promising therapeutic approach for the treatment of ...

    Authors: Robyn M Loureiro, Jo Ann Dumin, Timothy D McKee, Wesley F Austin, Nathan O Fuller, Jed L Hubbs, Ruichao Shen, Jeff Jonker, Jeff Ives, Brian S Bronk and Barbara Tate

    Citation: Alzheimer's Research & Therapy 2013 5:19

    Content type: Research

    Published on:

  21. Curcuminoids may improve pathological conditions associated with Alzheimer's disease. However, their therapeutic potential is limited by their exceedingly low bioavailability after oral administration. A metho...

    Authors: Wolfgang W Quitschke, Nicole Steinhauff and Jean Rooney

    Citation: Alzheimer's Research & Therapy 2013 5:16

    Content type: Research

    Published on:

  22. Heterogeneity in risk of conversion to Alzheimer's disease (AD) among individualswith mild cognitive impairment (MCI) is well known. Novel statistical methods thatare based on partially ordered set (poset) mod...

    Authors: Curtis Tatsuoka, Huiyun Tseng, Judith Jaeger, Ferenc Varadi, Mark A Smith, Tomoko Yamada, Kathleen A Smyth and Alan J Lerner

    Citation: Alzheimer's Research & Therapy 2013 5:14

    Content type: Research

    Published on:

  23. The US Food and Drug Administration approved a 23 mg daily dose of donepezil for treatment of moderate to severe Alzheimer's disease (AD) based on outcomes from a large trial comparing the 23 mg/day dose with ...

    Authors: Steven Ferris, Jeffrey Cummings, Daniel Christensen, Rachelle Doody, Martin Farlow, Marwan Sabbagh, Liang Liu, Joan Mackell and Randi Fain

    Citation: Alzheimer's Research & Therapy 2013 5:12

    Content type: Research

    Published on:

  24. The clinical, neuropsychiatric and neuroimaging features of patients who carry the important new C9ORF72 mutation are discussed in this special series of Alzheimer's Research & Therapy. First reported in November...

    Authors: Bruce L Miller

    Citation: Alzheimer's Research & Therapy 2013 5:7

    Content type: Editorial

    Published on:

  25. The Alzheimer's Drug Discovery Foundation's 13th International Conference on Alzheimer's Drug Discovery was held on 10-11 September 2012 in Jersey City, NJ, USA. This meeting report provides an overview of Alz...

    Authors: Rachel F Lane, Penny A Dacks, Diana W Shineman and Howard M Fillit

    Citation: Alzheimer's Research & Therapy 2013 5:5

    Content type: Meeting report

    Published on:

  26. The characteristics of dementia relating to excessive alcohol use have received increased research interest in recent times. In this paper, the neuropathology, nosology, epidemiology, clinical features, and ne...

    Authors: Nicole J Ridley, Brian Draper and Adrienne Withall

    Citation: Alzheimer's Research & Therapy 2013 5:3

    Content type: Review

    Published on:

  27. Memantine and cholinesterase inhibitors potentially offer additional benefits in Alzheimer's disease (AD) when used together. This study assessed the efficacy and safety of combination treatment with memantine...

    Authors: Alireza Atri, José L Molinuevo, Ole Lemming, Yvonne Wirth, Irena Pulte and David Wilkinson

    Citation: Alzheimer's Research & Therapy 2013 5:6

    Content type: Research

    Published on:

  28. 18F-florbetaben and positron emission tomography were used to examine the relationships between β-amyloid (Aβ) deposition, cognition, hippocampal volume, and white matter hyperintensities in mild cognitive impai....

    Authors: Kevin Ong, Victor L Villemagne, Alex Bahar-Fuchs, Fiona Lamb, Gaël Chételat, Parnesh Raniga, Rachel S Mulligan, Olivier Salvado, Barbara Putz, Katrin Roth, Colin L Masters, Cornelia B Reininger and Christopher C Rowe

    Citation: Alzheimer's Research & Therapy 2013 5:4

    Content type: Research

    Published on:

  29. With increasing knowledge of clinical in vivo biomarkers and the pathological intricacies of Alzheimer's disease (AD), nosology is evolving. Harmonized consensus criteria that emphasize prototypic illness continu...

    Authors: Benjamin Lam, Mario Masellis, Morris Freedman, Donald T Stuss and Sandra E Black

    Citation: Alzheimer's Research & Therapy 2013 5:1

    Content type: Review

    Published on:

  30. Lipoprotein-associated phospholipase A2 (Lp-PLA2) is a circulating enzyme with pro-inflammatory and oxidative activities associated with cardiovascular disease and ischemic stroke. While high plasma Lp-PLA2 activ...

    Authors: Julie E Davidson, Andrew Lockhart, Leslie Amos, Heide A Stirnadel-Farrant, Vincent Mooser, Marc Sollberger, Axel Regeniter, Andreas U Monsch and Michael C Irizarry

    Citation: Alzheimer's Research & Therapy 2012 4:51

    Content type: Research

    Published on:

\